<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004891</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-99048</org_study_id>
    <secondary_id>CDR0000067567</secondary_id>
    <secondary_id>NCI-G00-1695</secondary_id>
    <nct_id>NCT00004891</nct_id>
  </id_info>
  <brief_title>PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery</brief_title>
  <official_title>Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect&#xD;
      the extent of locally advanced primary rectal cancer and may also help to measure a patient's&#xD;
      response to treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well PET and CT scans detect residual or&#xD;
      metastatic disease in patients with locally advanced primary rectal cancer that can be&#xD;
      removed during surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to&#xD;
           CT scan at monitoring rectal cancer response to radiation and chemotherapy by&#xD;
           identifying residual rectal cancer in the rectal wall or pelvic lymph nodes in order to&#xD;
           optimize selection of patients suitable for a sphincter preserving rectal cancer&#xD;
           resection or a local excision.&#xD;
&#xD;
        -  Determine the accuracy of FDG-PET in detecting extrapelvic metastatic disease in primary&#xD;
           rectal cancer patients considered operable on the basis of currently accepted diagnostic&#xD;
           work-up, including abdominal CT scan and chest x-ray.&#xD;
&#xD;
      OUTLINE: This is a diagnostic study conducted concurrently with multimodality management.&#xD;
&#xD;
      Within 1-2 weeks prior to starting preoperative radiotherapy/chemotherapy, patients undergo&#xD;
      baseline positron emission tomography (PET) imaging of the thorax, abdomen, and pelvis.&#xD;
      Patients receive fludeoxyglucose F 18 (FDG) IV followed 45 minutes later by PET imaging.&#xD;
      Patients also undergo baseline CT imaging of the abdomen and pelvis. A CT scan of the chest&#xD;
      is obtained if the prestudy chest x-ray is abnormal.&#xD;
&#xD;
      Patients receive preoperative radiotherapy/chemotherapy. Within 4-6 weeks of completion of&#xD;
      radiotherapy/chemotherapy, patients undergo repeat FDG-PET imaging and CT scan. Patients&#xD;
      undergo surgical resection 1-2 weeks later.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan</measure>
    <time_frame>2 years</time_frame>
    <description>at monitoring rectal cancer response to radiation and chemotherapy by identifying residual rectal cancer in the rectal wall or pelvic lymph nodes in order to optimize selection of patients suitable for a sphincter preserving rectal cancer resection or a local excision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the accuracy of FDG-PET</measure>
    <time_frame>2 years</time_frame>
    <description>in detecting extrapelvic metastatic disease in primary rectal cancer patients considered operable on the basis of currently accepted diagnostic work-up, including abdominal CT scan and chest x-ray.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>primary resectable rectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Primary resectable rectal cancer as determined by currently accepted diagnostic&#xD;
             work-up, including CT scan and endorectal ultrasound (EUS)&#xD;
&#xD;
          -  Must meet criteria for preoperative radiotherapy and chemotherapy:&#xD;
&#xD;
               -  Bulky tumors and/or EUS evidence of T3-4 and/or N1 disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (i.e., greater than 175 mg/dL)&#xD;
&#xD;
          -  No intolerance of being inside PET scanner for duration of study&#xD;
&#xD;
          -  No vulnerable patients (e.g., mentally retarded or prisoners)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose G. Guillem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, Minsky BD, Paty PB, Weiser MR, Temple LK, Wong WD, Larson SM, Guillem JG. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol. 2008 Mar;15(3):704-11. doi: 10.1245/s10434-007-9626-y. Epub 2007 Sep 20. Erratum In: Ann Surg Oncol. 2008 Apr;15(4):1265. Leibold, Tobias [added].</citation>
    <PMID>17882490</PMID>
  </results_reference>
  <results_reference>
    <citation>Guillem JG, Puig-La Calle J Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan;43(1):18-24. doi: 10.1007/BF02237238.</citation>
    <PMID>10813118</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

